©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Transl Med. Dec 12, 2013; 2(3): 32-35
Published online Dec 12, 2013. doi: 10.5528/wjtm.v2.i3.32
Published online Dec 12, 2013. doi: 10.5528/wjtm.v2.i3.32
Peptide-based boronates: How to achieve tissue specificity in anticancer therapy
Nicola Micale, Department of Drug Sciences and Health Products, University of Messina, 98168 Messina, Italy
Author contributions: Micale N solely contributed to this article.
Correspondence to: Nicola Micale, PhD, Assistant Professor, Department of Drug Sciences and Health Products, University of Messina, Viale S.S. Annunziata, 75, 98168 Messina, Italy. nmicale@unime.it
Telephone: +39-90-6766419 Fax: +39-90-6766402
Received: July 24, 2013
Revised: September 4, 2013
Accepted: September 13, 2013
Published online: December 12, 2013
Processing time: 165 Days and 23.2 Hours
Revised: September 4, 2013
Accepted: September 13, 2013
Published online: December 12, 2013
Processing time: 165 Days and 23.2 Hours
Core Tip
Core tip: The design of “pro-soft” drugs is a promising strategy for enhancing the tissue specificity of drugs and for avoiding systemic adverse effects. This strategy might be applied to dipeptidyl boronic acids for use as proteasome inhibitors.